艰难梭菌耐药性的最新进展：耐药机制与药敏试验
Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.
作者信息
Peng Zhong, Jin Dazhi, Kim Hyeun Bum, Stratton Charles W, Wu Bin, Tang Yi-Wei, Sun Xingmin
机构信息
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China.
出版信息
J Clin Microbiol. 2017 Jul;55(7):1998-2008. doi: 10.1128/JCM.02250-16. Epub 2017 Apr 12.
Abstract
Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies of choice for infection. Several important mechanisms for antibiotic resistance have been described, including the acquisition of antibiotic resistance genes via the transfer of mobile genetic elements, selective pressure resulting in gene mutations, altered expression of redox-active proteins, iron metabolism, and DNA repair, as well as via biofilm formation. This update summarizes new information published since 2010 on phenotypic and genotypic resistance mechanisms in and addresses susceptibility test methods and other strategies to counter antibiotic resistance of .
摘要
口服抗生素如甲硝唑、万古霉素和非达霉素是治疗感染的首选疗法。已经描述了几种重要的抗生素耐药机制，包括通过移动遗传元件的转移获得抗生素耐药基因、导致基因突变的选择性压力、氧化还原活性蛋白表达的改变、铁代谢和DNA修复，以及通过生物膜形成。本综述总结了自2010年以来发表的关于[具体细菌名称未给出]表型和基因型耐药机制的新信息，并探讨了药敏试验方法和其他应对[具体细菌名称未给出]抗生素耐药性的策略。
相似文献
1
Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.
J Clin Microbiol. 2017 Jul;55(7):1998-2008. doi: 10.1128/JCM.02250-16. Epub 2017 Apr 12.
2
The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
Clin Microbiol Infect. 2018 Jul;24(7):724-731. doi: 10.1016/j.cmi.2017.10.008. Epub 2017 Oct 21.
3
Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia.
Int J Antimicrob Agents. 2018 Sep;52(3):411-415. doi: 10.1016/j.ijantimicag.2018.05.013. Epub 2018 May 23.
4
Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes.
Clin Microbiol Infect. 2015 Mar;21(3):248.e9-248.e16. doi: 10.1016/j.cmi.2014.09.017. Epub 2014 Oct 13.
5
In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
J Antimicrob Chemother. 2014 Jan;69(1):41-4. doi: 10.1093/jac/dkt302. Epub 2013 Jul 25.
6
High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
J Microbiol Immunol Infect. 2018 Jun;51(3):411-416. doi: 10.1016/j.jmii.2017.06.007. Epub 2017 Jun 29.
7
[Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002].
Med Dosw Mikrobiol. 2003;55(3):253-8.
8
Update on antimicrobial resistance in Clostridium difficile.
Yi Chuan. 2015 May;37(5):458-64. doi: 10.16288/j.yczz.15-131.
9
Antimicrobial resistance in Clostridium difficile.
Int J Antimicrob Agents. 2009 Dec;34(6):516-22. doi: 10.1016/j.ijantimicag.2009.09.012. Epub 2009 Oct 13.
10
Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia.
Anaerobe. 2015 Aug;34:80-3. doi: 10.1016/j.anaerobe.2015.05.001. Epub 2015 May 2.
引用本文的文献
1
Lipidomics, Microbiota, and Intestinal Infection Outcome.
Int J Mol Sci. 2025 Aug 24;26(17):8214. doi: 10.3390/ijms26178214.
2
Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2019-2023.
Can Commun Dis Rep. 2025 Jul 1;51(6-7):249-269. doi: 10.14745/ccdr.v51i67a04. eCollection 2025 Jul.
3
Minimum Inhibitory Concentration Increase in Isolates from Patients with Recurrence: Results from a Retrospective Single-Centre Cohort Study.
Microorganisms. 2025 Jun 28;13(7):1515. doi: 10.3390/microorganisms13071515.
4
Mobilome of Environmental Isolates of .
Antibiotics (Basel). 2025 Jul 4;14(7):678. doi: 10.3390/antibiotics14070678.
5
Characterization of Adult and Pediatric Healthcare-Associated and Community-Associated Clostridioides difficile Infections, Canada, 2015-2022.
Emerg Infect Dis. 2025 Jun;31(6):1109-1120. doi: 10.3201/eid3106.250182.
6
Community-Acquired Infection: The Fox Among the Chickens.
Int J Mol Sci. 2025 May 14;26(10):4716. doi: 10.3390/ijms26104716.
7
Potent Antimicrobial Activity of Fermentate Against Toxigenic Strains of .
Antibiotics (Basel). 2025 Mar 22;14(4):333. doi: 10.3390/antibiotics14040333.
8
Widespread heteroresistance to antibiotics in Lactobacillus species.
bioRxiv. 2025 Mar 24:2025.03.24.644958. doi: 10.1101/2025.03.24.644958.
9
Repurposing thioridazine as a potential CD2068 inhibitor to mitigate antibiotic resistance in infection.
Comput Struct Biotechnol J. 2025 Mar 1;27:887-895. doi: 10.1016/j.csbj.2025.02.036. eCollection 2025.
10
A Review of Therapies for Infection.
Antibiotics (Basel). 2024 Dec 31;14(1):17. doi: 10.3390/antibiotics14010017.
本文引用的文献
1
Diagnosis and Treatment of Infection (CDI).
Infect Dis Clin Pract (Baltim Md). 2016 Jan;24(1):3-10. doi: 10.1097/IPC.0000000000000350.
2
Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China.
J Clin Microbiol. 2017 Mar;55(3):801-810. doi: 10.1128/JCM.01898-16. Epub 2016 Dec 14.
3
Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion.
Braz J Infect Dis. 2016 Sep-Oct;20(5):476-81. doi: 10.1016/j.bjid.2016.07.004. Epub 2016 Aug 16.
4
Clostridium difficile infection: a review of current and emerging therapies.
Ann Gastroenterol. 2016 Apr-Jun;29(2):147-54. doi: 10.20524/aog.2016.0006.
5
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.
Antibiotics (Basel). 2015 Jul 10;4(3):267-98. doi: 10.3390/antibiotics4030267.
6
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.
Ther Adv Infect Dis. 2016 Feb;3(1):23-42. doi: 10.1177/2049936115622891.
7
The importance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for correct identification of Clostridium difficile isolated from chromID C. difficile chromogenic agar.
J Microbiol Immunol Infect. 2017 Oct;50(5):723-726. doi: 10.1016/j.jmii.2015.12.002. Epub 2016 Jan 11.
8
Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance.
Genes (Basel). 2015 Dec 21;6(4):1347-60. doi: 10.3390/genes6041347.
9
Susceptibility of Clostridium difficile to the food preservatives sodium nitrite, sodium nitrate and sodium metabisulphite.
Anaerobe. 2016 Feb;37:67-71. doi: 10.1016/j.anaerobe.2015.12.004. Epub 2015 Dec 15.
10
Subinhibitory concentrations of metronidazole increase biofilm formation in Clostridium difficile strains.
Pathog Dis. 2016 Mar;74(2). doi: 10.1093/femspd/ftv114. Epub 2015 Dec 9.
Zotero 插件